Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Alexandria Venture Investments
AddedFeb 13, 2024
UpdatedJun 28, 2026
Alexandria Venture Investments

Alexandria Venture Investments

Operating

California-based Alexandria Venture Investments pioneers in venture capital for real estate, tech, and healthcare sectors.

Location
Pasadena, CA, US
Founded
1996
Firm
Compare
Portfolio
Employees
Website

Investments

SonoThera
SonoThera
Series B

Total Raised

$185.8M

Rounds

2

Series B$125MJune 2026
Elo Life Systems
Elo Life Systems

Total Raised

$56.5M

Rounds

3

Series A$20.5MJanuary 2024
Tr1x
Tr1x

Total Raised

$75M

Rounds

2

Series A$75MJanuary 2024
Zymochem
Zymochem

Total Raised

$29.6M

Rounds

6

Series A$21MJanuary 2024
Remix Therapeutics
Remix Therapeutics

Total Raised

$211M

Rounds

4

Series Unknown$60MJanuary 2024
Tome Biosciences
Tome Biosciences

Total Raised

$213M

Rounds

1

Series A$213MDecember 2023
Odyssey Therapeutics
Odyssey Therapeutics

Total Raised

$487M

Rounds

3

Series C$101MDecember 2023
Seismic Therapeutic
Seismic Therapeutic

Total Raised

$222M

Rounds

2

Series B$121MDecember 2023
Alto Neuroscience
Alto Neuroscience

Total Raised

$239.3M

Rounds

10

Series C$45MNovember 2023
Triveni Bio
Triveni Bio
Series C

Total Raised

$272M

Rounds

3

Series A$92MOctober 2023
Deka Biosciences
Deka Biosciences

Total Raised

$91.4M

Rounds

4

Series B$20MSeptember 2023
Arialys Therapeutics
Arialys Therapeutics

Total Raised

$58M

Rounds

1

Seed$58MSeptember 2023
Rome Therapeutics
Rome Therapeutics

Total Raised

$199M

Rounds

3

Series B$72MSeptember 2023
Georgiamune
Georgiamune

Total Raised

$75M

Rounds

2

Series A$75MAugust 2023
Solu Therapeutics
Solu Therapeutics

Total Raised

$31M

Rounds

1

Seed$31MAugust 2023
AltPep
AltPep

Total Raised

$76M

Rounds

2

Series B$52.9MJune 2023
Bitterroot Bio
Bitterroot Bio

Total Raised

$145M

Rounds

1

Series A$145MJune 2023
Boundless Bio
Boundless Bio

Total Raised

$251.4M

Rounds

3

Series C$100MMay 2023
Ten63 Therapeutics
Ten63 Therapeutics

Total Raised

$15.9M

Rounds

3

Series A$15.9MMay 2023
Orbital Therapeutics
Orbital Therapeutics

Total Raised

$270M

Rounds

2

Series A$270MApril 2023
Harpe Bio
Harpe Bio

Total Raised

$14.7M

Rounds

4

Convertible Note$10.5MApril 2023
Torl Biotherapeutics
Torl Biotherapeutics

Total Raised

$158M

Rounds

1

Series B$158MApril 2023
Function Oncology
Function Oncology

Total Raised

$28M

Rounds

1

Series A$28MApril 2023
Ring Therapeutics
Ring Therapeutics

Total Raised

$253.5M

Rounds

3

Series C$86.5MMarch 2023
Chroma Medicine
Chroma Medicine

Total Raised

$260M

Rounds

3

Series B$135MMarch 2023